Its elimination half-life is three days. Co-administration of fluoxetine or paroxetine may increase sertindole plasma levels. Co-administration of carbamazepine or phenytoin my decrease serum levels. Metabolites of sertindole do not appear to have any therapeutic effect. Pharmacokinetics do not appear to be significantly affected by age, sex, race or renal impairment.
Hepatic impairment implies that care is needed in calculating effective dosages.
These adverse events did not appear to be dose-dependent. Adrenergic side effects such as postural hypotension and sinus tachycardia tend to diminish with continued dosing. Extrapyramidal symptoms do not exceed those of placebo. There appears to be no tendency to increase or initiate tardive dyskinesia or akathisia. There is some evidence to suggest short-term prolactin increases in some, patients.